First patient enrolled in massive heart failure trial

May 5, 2026 - 23:20

A major clinical trial that could change the treatment landscape for millions of heart failure patients has officially begun, with the first participant now enrolled. The study, known as BENEFIT-HF, is a large-scale randomized investigation into the effectiveness of CVRx's Barostim device, an implant designed to regulate the autonomic nervous system.

The Barostim system works by electrically stimulating baroreceptors in the carotid artery. These sensors tell the brain to calm the sympathetic nervous system, which is often overactive in heart failure. By reducing this stress response, the device aims to improve the heart's pumping efficiency and reduce symptoms like fatigue and shortness of breath.

Currently, the device is approved for a narrower group of patients who do not respond well to standard medications. The BENEFIT-HF trial is much broader. It will enroll hundreds of patients across multiple medical centers to see if Barostim can help a wider population, including those with less severe heart failure or those who cannot tolerate certain drugs.

If the trial produces positive results, it could lead to expanded insurance coverage and regulatory approvals. That would give doctors a new tool to treat a condition that affects over 60 million people worldwide. The study is expected to take several years to complete, but the enrollment of the first patient marks a critical step forward in the search for better heart failure therapies.